Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Modafinil
Drug ID BADD_D01484
Description Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactivation and euphoria. The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Modafinil activates glutamatergic circuits while inhibiting GABA.
Indications and Usage To improve wakefulness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy.
Marketing Status approved; investigational
ATC Code N06BA07
DrugBank ID DB00745
KEGG ID D01832
MeSH ID D000077408
PubChem ID 4236
TTD Drug ID D07HQC
NDC Product Code 46438-0655; 63285-000; 63552-066; 70771-1051; 71205-477; 46438-0102; 65862-602; 60505-2526; 65862-601; 68071-2844; 69452-343; 65129-1102; 71205-544; 71335-1096; 63459-201; 68084-721; 70771-1052; 71335-1402; 72578-006; 63459-101; 23155-604; 71335-1793; 71610-685; 71335-1122; 72578-005; 50268-571; 55253-801; 57237-155; 60505-2527; 62332-385; 69452-342; 71335-1173; 0904-6423; 58175-0378; 63552-067; 23155-605; 46708-385; 55253-802; 63285-001; 46708-386; 63629-7315; 68084-621; 68788-7432; 68788-8280; 0904-6424; 0904-6791; 0904-6792; 72761-023; 42043-161; 50268-570; 57237-154; 62332-386; 63629-4998; 68788-8079; 63415-0036; 65862-576; 42043-160; 43353-925
UNII R3UK8X3U3D
Synonyms Modafinil | 2-((Diphenylmethyl)sulfinyl)acetamide | Vigil | Sparlon | Nuvigil | Alertec | Benzhydrylsulfinylacetamide | Armodafinil | 2-((R)-(Diphenylmethyl)sulfinyl)acetamide | R-Modafinil | R Modafinil | Provigil | Modiodal | CRL 40476 | CRL-40476
Chemical Information
Molecular Formula C15H15NO2S
CAS Registry Number 68693-11-8
SMILES C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Bradycardia02.03.02.002--Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Cardiac arrest02.03.04.0010.000412%
Cataplexy19.02.02.003; 17.15.01.003; 15.05.04.0100.001852%Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Chills15.05.03.016; 08.01.09.001--
Completed suicide19.12.01.001; 08.04.01.0100.000617%Not Available
Condition aggravated08.01.03.0040.000823%Not Available
Confusional state19.13.01.001; 17.02.03.005--
Conjunctivitis11.01.06.012; 06.04.01.002--
Constipation07.02.02.001--
Cough22.02.03.0010.000617%
Cyanosis23.06.04.005; 02.11.04.004; 24.03.01.007; 22.02.02.0070.000412%
Cystitis11.01.14.001; 20.03.02.002--
Delusion19.10.01.001--
Depressed level of consciousness17.02.04.0020.000412%
Depressed mood19.15.02.0010.001317%Not Available
Depression19.15.01.0010.002017%
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Disorientation19.13.01.002; 17.02.05.0150.000412%Not Available
Disturbance in attention17.03.03.001; 19.21.02.0020.000823%
Dizziness17.02.05.003; 02.11.04.006; 24.06.02.0070.004116%
Drug abuse19.07.06.0100.001852%Not Available
Drug dependence19.07.06.0110.001235%Not Available
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.015--Not Available
Drug hypersensitivity10.01.01.0010.005021%Not Available
Drug ineffective08.06.01.0060.024943%Not Available
Drug interaction08.06.03.0010.000823%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 9 Pages